Merck & Co. (MRK) is testing a new prostate cancer drug and successful drug studies to fight liver cancer and melanoma. Tcr2 Therapeutics (TCRR) is turning focus to ovarian cancer and has a large addressable market. "Merck has dominance in the oncology space with KEYTRUDA. There has been a flight to quality stocks like MRK in a rising interest rate environment. Tcr2 Therapeutics works on the cell therapy side," says Mara Goldstein.
03 Oct 2022
Morning Trade Live
18 Aug 2023
Morning Trade Live
10 Jul 2023
The Watch List
21 Sep 2023
Fast Market
13 Sep 2023
Trading 360
03 Aug 2023